advertisement

Topcon

Abstract #19343 Published in IGR 9-3

Effect of nerve regeneration factor on expression of inducible-nitric oxide synthase in retina with experimental intraocular hypertension

Guan H; Huang Z; Ding F; Gu X
Chinese Ophthalmic Research 2007; 25: 325-328


OBJECTIVE: It is generally believed nitric oxide is one of the toxins which result in retinal ganglion cells (RGCs) apoptosis. Nerve regeneration factor (NRF) from Chinese medicine has neuroprotective effect. This article studied whether NRF can protect RGCs with experimental intraocular hypertention by downregulating expression of inducible-nitric oxide synthase(i-NOS) in rabbit retina. METHODS: Experimental high intraocular pressure (IOP) models were established by balance salt solution perfusion into anterior chamber in the right eyes of 12 rabbits. 4.5 μg of NRF or 5 μl of PBS(0.1 mol/L) was injected respectively into vitreous body cavity of right eyes of rabbits in NRF group (n = 6) or PBS group (n = 6) before perfusion and at 4, 7 days in postperfusion. The left eyes of NRF group and PBS group served as normal control group. IOP was detected using Sehiotz tonometer before and after perfusion 4, 7, 14 days. The RT-PCR was used to examine the effect of NRF on expression of i-NOSmRNA in retina. RESULTS: No significant differences were found in IOP between NRF and PBS group at different time point (t = 0.241, P = 0. 728; t = 0.438, P = 0.629; t = 0.256, P = 0.821; t = 1.557, P = 0.183). The expression level of i-NOSmRNA in NRF group,PBS group and normal control group was (68.70 (plus or minus) 14.55), (146.00 ± 5.01) and (50.02 ± 3.50) .respectively. The expression level of i-NOSmRNA in NRF group (OD value) was significantly decreased compared with PBS group (P = 0.000), but remained a higher level in comparison with normal control group. CONCLUSION: NRF could down-regulate the expression of i-NOSmRNA in retina in high IOP eyes, which could protect retinal ganglion cells from glaucomatous neuropathy. LA: Chinese

Dr. H. Guan, Nantong University, Nantong 226001, China. Guanhj@ntu.edu.cn


Classification:

11.8 Neuroprotection (Part of: 11 Medical treatment)
11.14 Investigational drugs; pharmacological experiments (Part of: 11 Medical treatment)
3.5 Molecular biology incl. SiRNA (Part of: 3 Laboratory methods)
5.3 Other (Part of: 5 Experimental glaucoma; animal models)



Issue 9-3

Change Issue


advertisement

Oculus